Background: Organic coronary artery stenosis is a significant prognostic factor in patients with coronary spastic angina (CSA), so the present study was focused on assessing the impact of intermediate fixed stenosis at sites of provoked spasm on the long-term outcomes of CSA patients. Methods and Results: CSA patients diagnosed on the basis of ergonovine-provoked spasm were enrolled and the clinical background and long-term prognosis of CSA patients with intermediate fixed stenosis at the site of provoked spasm (with-fixed-stenosis group, n=37) and those without fixed stenosis (without-fixed-stenosis group, n=126) were retrospectively compared. During the follow-up period (average 4.01 years for with-fixed-stenosis, 4.47 years for without-fixed-stenosis), the with-fixed-stenosis group had a significantly lower event-free survival rate, as well as a higher frequency of admission for unstable angina and percutaneous coronary intervention than the without-fixed-stenosis group, whereas the survival rate did not differ significantly between the 2 groups. In the multivariate analysis, intermediate fixed stenosis at the site of provoked spasm was a predictor of long-term major adverse cardiac events (MACE). Conclusions: Intermediate fixed stenosis at the site of ergonovine-provoked spasm is an independent risk factor for MACE during the long-term period in CSA patients. (Circ J 2009; 73: 699 -704) 
oronary artery spasm plays an important role in the pathogenesis of angina, acute myocardial infarction (AMI), arrhythmia, and sudden death. The prognosis for most patients with coronary spastic angina (CSA) is considered relatively satisfactory if adequately treated by vasodilators, such as calcium-channel antagonists. However, coronary spasm frequently occurs in mildly narrowed segments, and it is not uncommon for mild coronary atherosclerotic changes to progress and become a significant organic stenosis during long-term follow-up of patients with CSA. Previous experimental and clinical studies have indicated the potential role of coronary spasm in the progression of organic stenosis, 1,2 and another recent report has also highlighted the higher incidence of acetylcholine-provoked spasm in the infarct-related coronary arteries than in non-infarct-related coronary arteries in patients with recent myocardial infarction (MI). 3 Indeed, the accumulating evidence demonstrates that the presence of organic coronary artery stenosis is a significant prognostic factor in CSA patients. [4] [5] [6] [7] [8] Thus, in the present study we focused on intermediate fixed coronary artery stenosis at the site of spasm in the provocation test and assessed its effect on long-term outcomes in patients with CSA. We compared the long-term prognosis patients with intermediate fixed coronary artery stenosis at a site of ergonovineprovoked spasm with that patients without such a stenosis.
Methods

Patient Population
From April 1995 to January 2007, 172 consecutive patients with a diagnosis of CSA confirmed by ergonovine provocation test and who were admitted to Kyoto First Red Cross Hospital were enrolled in the present study. Data for clinical background and follow-up after discharge were obtained for 163 of them. CSA was diagnosed on the basis of angiographically documented coronary spasm combined with symptoms of myocardial ischemia or ischemic ST segment changes on 12-lead ECG or both. Coronary angiography (CAG), including the ergonovine provocation test, was performed using standard techniques without antiangina medications, except for patients for whom it was judged dangerous to discontinue vasodilators. Coronary stenosis was evaluated according to the American Heart Association classification. 9 After baseline CAG, the intracoronary ergonovine provocation test was performed in patients who had the potential to show coronary spasm based on their interview or clinical examination. Ergonovine in 0.9% solution was injected incrementally into the right coronary artery to a maximum total dose of 40 μg, or into the left coronary artery to a maximum total dose of 60 μg, until coronary spasm was provoked or until the maximal dose was given. Coronary spasm was defined as transient vessel narrowing ≥99%. When spontaneous coronary spasm defined as ≥90% was confirmed on the baseline CAG, the spasm provocation test was not performed, and if the coronary stenosis was released by intracoronary administration of isosorbide dinitrate (ISDN), the case was considered positive. The degree of ST-segment depression was measured 80 ms after the J point. Positive ECG changes were defined as (1) ST-segment elevation ≥0.2 mV in at least 2 related leads and (2) ST-segment depression ≥0.1 mV of a horizontal or downsloping type or ≥0.2 mV of a junctional type. After the provocation test, coronary arteries were measured after the intracoronary administration of ISDN (2.0-5.0 mg) to evaluate the organic stenosis. Significant coronary stenosis was defined as ≥75% stenosis of the right, left anterior descending or left circumflex coronary artery and the major branches, or ≥50% stenosis of the left main trunk (LMT). Non-significant stenosis was defined as coronary arterial narrowing less than a significant stenosis. Patients with either angiographically normal coronary arteries or non-significant stenosis were classified as having 0-vessel disease. Patients with ≥90% organic stenosis in the right, left anterior descending or left circumflex coronary artery and major branches or ≥75% stenosis in the LMT were excluded so that the study population had no significant organic stenosis (ie, ≥75%) in any part of the coronary tree other than at the site of ergonovine-provoked spasm. In these CSA patients, intermediate fixed coronary stenosis was defined as moderate coronary arterial narrowing (ie, 50%, 75%) at the site of provoked spasm after intracoronary ISDN injection. The lesions were confirmed to be functionally non-significant stenoses by an exercise stress test or stress perfusion imaging. After CAG, left ventriculography was subsequently performed in the right anterior oblique view. We retrospectively compared the clinical background, coronary risk factors, initial medications, and long-term prognosis between CSA patients with intermediate fixed coronary artery stenosis (with-fixed-stenosis group, n=37) and those without intermediate fixed coronary artery stenosis (without-fixed-stenosis group, n=126).
Data Collection
The patients' demographic information, cardiovascular history, and risk factors (ie, smoking, hyperlipidemia, hypertension, diabetes mellitus, obesity) were recorded. Smokers were defined as patients who had smoked at the time of diagnosis of CSA. Hyperlipidemia was defined as either total cholesterol ≥220 mg/dl, low-density lipoprotein cholesterol ≥140 mg/dl, fasting triglycerides ≥150 mg/dl or the use of lipid-lowering treatment. Hypertension was defined as systemic blood pressure ≥140/90 mmHg or the use of antihypertensive treatment. Diabetes mellitus was defined as fasting blood sugar ≥126 mg/dl, postprandial blood sugar ≥200 mg/dl, hemoglobin A1c ≥6.5 or the use of treatment. Obesity was defined as a body mass index ≥25 kg/m 2 . The study protocol was approved by the hospital's Ethics Committee.
Follow-up
Follow-up data were obtained from hospital records or by interviewing (directly or by telephone) the patients, their families or their personal physicians as of January 31, 2007. Major adverse cardiac events (MACE) included ischemic events and cardiac death. Non-fatal AMI and hospitalization for unstable angina requiring percutaneous revascularization were included as ischemic events. Unstable angina pectoris (UAP) was defined as new angina, including angina on effort, worsening angina, and refractory angina. Sudden death and death associated with heart failure, malignant arrhythmia, and AMI were included as cardiac deaths. The primary endpoint was MACE during the follow-up period.
Statistical Analysis
Data are expressed as mean ± SD. The with-fixed-stenosis and the without-fixed-stenosis groups were compared using the chi-square test for discrete variables and the unpaired Student's t-test for continuous variables, according to standard statistical methods. Survival and event-free survival curves are displayed using the Kaplan-Meier method, and differences were compared using the log-rank test. Correlates of MACE during the follow-up period were determined by Cox model analysis. In all analyses, significance was accepted at P<0.05. Table 1 shows the coronary angiographic data for the study population. Approximately 70% of the CSA patients had a total occlusion in the provocation test and approximately 50% of the overall study population had no angiographically narrowing at the site of provoked spasm.
Results
Angiographic Characteristics
Patient Characteristics
The clinical characteristics and initial medications of the 2 groups are summarized in Table 2 . The with-fixed-stenosis group had a higher frequency of males than the withoutfixed-stenosis group, but this difference was not significant. The with-fixed-stenosis group had a higher prevalence of diabetes mellitus than the without-fixed-stenosis group, whereas the without-fixed-stenosis group had higher prevalence of smoking and obesity than the with-fixed-stenosis group. The patients from the with-fixed-stenosis group were more likely to have been administered nitrates, statins, and aspirin as their initial medication after angiographic diagnosis of CSA than the patients from the without-fixedstenosis group.
Prognosis
The mean follow-up time was 4.01 years for the withfixed-stenosis group and 4.47 years for the without-fixedstenosis group. Overall, the CSA patients had an 86.6% survival rate and a 64.8% event-free survival rate at 10 years (Figure 1) . During the follow-up period, the withfixed-stenosis group had a significantly lower event-free Table 3 . survival rate than the without-fixed-stenosis group, whereas the survival rate did not differ significantly between the 2 groups (Figure 2) . The with-fixed-stenosis group had a 72.2% survival rate at 10 years compared with a 90.4% survival rate in the without-fixed-stenosis group (P=0.976 by log-rank test; Figure 2A) . The with-fixed-stenosis group had a 21.7% event-free survival rate at 10 years compared with a 76.7% event-free survival rate in the without-fixedstenosis group (P<0.0001 by log-rank test; Figure 2B ). Table 3 lists the MACE for the with-fixed-stenosis group and the without-fixed-stenosis group during the entire follow-up period, during which there were 2 deaths in the with-fixed-stenosis group and 8 in the without-fixed-stenosis group. The 2 deaths in the with-fixed-stenosis group were 2 cardiac-related deaths (1 sudden death, 1 heart failure). The 8 deaths in the without-fixed-stenosis group comprised 2 cardiac-related deaths (both sudden death) and 6 non-cardiac-related deaths. Overall MACE, ischemic events, admission for UAP, and percutaneous coronary intervention (PCI) for UAP were more frequent in the withfixed-stenosis group than in the without-fixed-stenosis group ( Table 3) . Table 4 shows detailed data regarding 10 patients who underwent PCI for non-fatal AMI and UAP during the follow-up period; all were male. The culprit lesions in 8 of the 10 cases already had 50% or 75% fixed stenosis at the time of initial CAG, and the culprit lesions in 6 of the 10 cases coincided with the site of provoked spasm at the time of initial CAG ( Table 5 ). The predictor of MACE during long-term follow-up period in patients with CSA was the presence of intermediate fixed coronary stenosis at the site of provoked spasm (hazard ratio (HR) 4.538; 95% confidence interval (CI) 1.728-11.922, P=0.002).
Discussion
The major finding of the present study is that among patients with confirmed CSA by ergonovine-provoked coronary artery spasm (≥99% narrowing), during long-term follow-up those with intermediate fixed stenosis at the site of ergonovine-provoked spasm had a significantly lower event-free survival rate, as well as a higher frequency of admission for UAP and PCI for UAP, than patients without, although the survival rate did not differ significantly between the 2 groups. In the multivariate analysis, the presence of intermediate fixed coronary stenosis at the site of the ergonovine-provoked spasm was an independent predictor of MACE.
This study is the first to investigate the effects of intermediate fixed coronary stenosis at the site of ergonovineprovoked spasm on the long-term outcome of patients with CSA. Although data regarding the long-term prognosis of CSA patients is limited, previous reports have shown that the prognosis for most patients with CSA is relatively good if they are continuously medicated with calcium-channel antagonists and stop smoking. 4, 6, 7, 10 In contrast, multivessel coronary spasm and the extent of obstructive coronary artery disease have been reported as significant predictors of the long-term prognosis of patients with CSA. 6, 8 Most patients with multivessel spasm have normal coronary arteries on CAG, and tend to be refractory to calciumchannel antagonists and other vasodilators, thus having a high risk of malignant arrhythmia or sudden death. 6, [10] [11] [12] On the other hand, it is not uncommon for mild coronary vessel narrowing to progress and become a significant organic stenosis in the long-term in patients with CSA. Indeed, previous experimental and clinical studies have indicated the potential role of coronary spasm in the progression of organic stenosis. 1, 2, 13, 14 Intramural hemorrhage, neointimal hyperplasia, and thrombus formation are proposed mechanisms by which coronary spasm could provoke progression of organic stenosis and AMI. 1,2 Chronic lowgrade inflammation, which has been reported as associated with coronary spasm, 15 might contribute to plaque progression. Still another recent report has pointed out that the incidence of acetylcholine-provoked spasm is higher in the infarct-related coronary artery than in non-infarct-related coronary arteries in patients with recent MI. 3 Thus, we hypothesized that mild atherosclerotic changes at the site of provoked spasm are likely to progress and trigger ischemic events, so in the present study we focused on the intermediate fixed stenosis at the site of ergonovine-provoked spasm in order to examine the long-term prognosis of patients with CSA.
CSA patients with intermediate fixed stenosis at the site of provoked spasm had a significantly lower event-free survival rate, as well as a higher frequency of admission for UAP and PCI for UAP during the follow-up period than the CSA patients without intermediate fixed stenosis. Moreover, we have demonstrated for the first time that the presence of intermediate fixed coronary stenosis at the site of ergonovine-provoked spasm is an independent predictor of MACE during the long-term follow-up period. Unexpectedly, of the 10 CSA patients who underwent PCI during the long-term follow-up period, only 6 of the 10 culprit lesions requiring PCI coincided with the sites of ergonovine-provoked spasm. However, 8 of the 10 PCI cases had 50% or 75% fixed stenosis at the site of ergonovine-provoked spasm at the time of initial CAG and the culprit lesions in 8 of the 10 PCI cases already had 50% or 75% fixed stenosis at that time. In addition, except for non-fatal AMI cases, the culprit lesions were all derived from the intermediate fixed stenosis on the initial CAG in the with-fixed-stenosis group, and progression of the intermediate fixed stenosis contributed to the higher prevalence of PCI for UAP during the follow-up period in the with-fixed-stenosis group. Taken together, not only the intermediate fixed stenosis at the site of provoked spasm but also the organic non-significant stenosis at other sites might be important determinants of the long-term prognosis of patients with CSA. Thus, careful attention and adequate medication should be given to CSA patients with intermediate fixed stenosis. Coronary multidetector computed tomography might be a suitable imaging modality for evaluating coronary organic lesions during the follow-up period in these patients, because a previous report has shown that calcified lesions are less frequently present in the coronary plaque at the sites of coronary spasm. 16 Moreover, in addition to calcium-channel antagonists, intensive treatment with statins or aspirin might be essential for improving the prognosis of CSA patients with intermediate fixed stenosis.
Data regarding the long-term prognosis of patients with CSA is limited. In our study, survival at 1, 3, 5, and 10 years was 98.0%, 96.6%, 92.9%, and 86.6%, respectively, consistent with previous reports from Japanese investigators. [6] [7] [8] In contrast, previous reports concerning CSA patients in Western populations have shown lower survival rates than in our present report, as well as than in the other reports based on the Japanese populations. 4, 5 This significant difference in the survival rate of CSA patients during the follow-up period between Japanese and Western populations might be ascribed to differences in the prevalence and extent of organic coronary artery stenosis in the 2 populations. Another possibility is differences in the frequency of calcium-channel antagonists as the initial treatment. Indeed, our present study populations had a lower prevalence of organic coronary stenosis and were more likely to be taking calcium-channel antagonists as the initial treatment, compared with patients in the reports concerning Western populations. 4, 5 In the present study, the survival rate did not differ significantly between the CSA patients with intermediate fixed stenosis and those without, which is inconsistent with the previous reports in Western populations. 4, 5 The difference in the severity of organic coronary artery stenosis and the degree of concomitant left ventricular dysfunction might contribute to this discrepancy.
Study Limitations
First, this is a retrospective single-center analysis of a small number of patients. Second, we have not accounted for intermediate fixed stenosis at other sites in the coronary tree, which might also be a predictive risk of long-term MACE. Third, we had no data regarding the exchange of medications during the follow-up period. Moreover, the ergonovine-provocation test, not the acetylcholine-provocation test was used and coronary spasm was defined as a transient vessel narrowing ≥99%. Thus, in most cases with CSA, we could not perform the provocation test in both the RCA and LCA without intermittent ISDN administration and that could be a reason for the lower frequency of multivessel spasm in our study. 3, 8, 17 Further, larger prospective studies are needed to examine the long-term prognosis of Japanese patients with CSA and to ascertain the prognostic effect of intermediate fixed stenosis at the site of ergonovine-provoked spasm on long-term outcomes.
Conclusion
The present study provides evidence that in CSA patients confirmed by ergonovine-provoked coronary artery spasm (≥99% narrowing), during the long-term follow-up period those with intermediate fixed stenosis at the site of ergonovine-provoked spasm had a significantly lower event-free survival rate, as well as a higher frequency of admission for UAP and PCI for UAP, than the CSA patients without, although the survival rate did not differ significantly between the 2 groups. The presence of intermediate fixed coronary stenosis at the site of ergonovine-provoked spasm was an independent predictor of MACE.
